PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics Ltd. (NASDAQ:ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the results from an analytical validation study confirming that the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal™ (“Reveal”), can now be used with liquid-based cytology samples (ThinPrep®). The data will be presented in a poster at the upcoming 86th Annual Meeting of the American Thyroid Association taking place from September 21-25, 2016 at the Sheraton Denver Downtown Hotel in Denver, Colorado.
